MMP9 Monoclonal Antibody (GE-213) | Invitrogen MA5-13595 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

MMP9 Monoclonal Antibody (GE-213)

catalog :

MA5-13595

quantity :

500 uL

price :

US 480.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

GE-213

reactivity :

human

application :

immunohistochemistry, immunoprecipitation, immunohistochemistry - frozen section

citations: 50

Reference
Laçin N, İzol S, Ipek F, Tuncer M. Ganoderma lucidum, a promising agent possessing antioxidant and anti-inflammatory effects for treating calvarial defects with graft application in rats. Acta Cir Bras. 2019;34:e201900904 pubmed publisher
Chen X, Yu T, Zhang J, Li Y, Chen H, Yang G, et al. CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis. Oncogene. 2017;36:5045-5057 pubmed publisher
Otsuki S, Sawada H, Yodoya N, Shinohara T, Kato T, Ohashi H, et al. Potential contribution of phenotypically modulated smooth muscle cells and related inflammation in the development of experimental obstructive pulmonary vasculopathy in rats. PLoS ONE. 2015;10:e0118655 pubmed publisher
Youssef N, Hakim S. Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women. Diagn Pathol. 2014;9:136 pubmed publisher
Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, Masunari T, et al. Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS ONE. 2013;8:e78730 pubmed publisher
Wang J, Huan S, Hsieh K, Chou H, Hsiao G, Jayakumar T, et al. Inhibitory effect of midazolam on MMP-9, MMP-1 and MMP-13 expression in PMA-stimulated human chondrocytes via recovery of NF-?B signaling. Arch Med Sci. 2013;9:332-9 pubmed publisher
Hsieh H, Lin C, Hsiao L, Yang C. High glucose induces reactive oxygen species-dependent matrix metalloproteinase-9 expression and cell migration in brain astrocytes. Mol Neurobiol. 2013;48:601-14 pubmed publisher
Fanelli M, Chinen L, Begnami M, Costa W, Fregnami J, Soares F, et al. The influence of transforming growth factor-?, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012;61:153-61 pubmed publisher
Tao Y, Chai D, Ma L, Zhang T, Feng Z, Cheng Z, et al. Identification of distinct gene expression profiles between esophageal squamous cell carcinoma and adjacent normal epithelial tissues. Tohoku J Exp Med. 2012;226:301-11 pubmed
Cheng C, Hsieh H, Hsiao L, Yang C. PI3-K/Akt/JNK/NF-?B is essential for MMP-9 expression and outgrowth in human limbal epithelial cells on intact amniotic membrane. Stem Cell Res. 2012;9:9-23 pubmed publisher
Lee W, Chung C, Hsiao C, Chou Y, Hsueh P, Yang P, et al. Suppression of matrix metalloproteinase-9 expression by andrographolide in human monocytic THP-1 cells via inhibition of NF-?B activation. Phytomedicine. 2012;19:270-7 pubmed publisher
Lin C, Jin J, Yu C, Tsai W. Expression of LGR8 and related biomarkers in hepatocellular carcinoma: correlation with clinicopathological parameters. Chin J Physiol. 2011;54:161-8 pubmed
Bidgoli S, Karimi M, Asami Z, Baher H, Djamali Zavarhei M. Association between testicular Aryl hydrocarbon Receptor levels and idiopathic male infertility: a case-control study in Iran. Sci Total Environ. 2011;409:3267-73 pubmed publisher
Alshenawy H. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. Ann Diagn Pathol. 2010;14:387-95 pubmed publisher
Gonzalez L, Junquera S, del Casar J, Gonzalez L, Marín L, Gonzalez Reyes S, et al. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Hum Pathol. 2010;41:980-9 pubmed publisher
Escaff S, Fernandez J, Gonzalez L, Suarez A, Gonzalez Reyes S, Gonzalez J, et al. Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer. 2010;102:922-9 pubmed publisher
Gonzalez L, Gonzalez Reyes S, Junquera S, Marin L, Gonzalez L, del Casar J, et al. Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events. J Cancer Res Clin Oncol. 2010;136:1313-21 pubmed publisher
Muller M, Beck I, Gadesmann J, Karschuk N, Paschen A, Proksch E, et al. MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells. Mod Pathol. 2010;23:511-21 pubmed publisher
Chou Y, Sheu J, Chung C, Chen C, Lin F, Hsu M, et al. Nuclear-targeted inhibition of NF-kappaB on MMP-9 production by N-2-(4-bromophenyl) ethyl caffeamide in human monocytic cells. Chem Biol Interact. 2010;184:403-12 pubmed publisher
del Casar J, Carreño G, Gonzalez L, Junquera S, Gonzalez Reyes S, Gonzalez J, et al. Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer. J Cancer Res Clin Oncol. 2010;136:1049-58 pubmed publisher
Lee W, Kim S, Ryu W. Progression and observational frequency of atheromatous plaques in autopsied coronary arteries. Korean Circ J. 2009;39:399-407 pubmed publisher
del Casar J, Gonzalez Reyes S, Gonzalez L, Gonzalez J, Junquera S, Bongera M, et al. Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol. 2010;136:811-9 pubmed publisher
Kean M, Williams K, Skalski M, Myers D, Burtnik A, Foster D, et al. VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci. 2009;122:4089-98 pubmed publisher
Ryu H, Lee J, Yang S, Park H, Choi S, Jung K, et al. Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells. J Biol Chem. 2009;284:35692-701 pubmed publisher
Guo Z, Sun X, He Z, Jiang Y, Zhang X, Zhang J. Matrix metalloproteinase-9 potentiates early brain injury after subarachnoid hemorrhage. Neurol Res. 2010;32:715-20 pubmed publisher
Lee W, Kim S, Hong S, Lee T, Park E, Kim H, et al. Atherosclerotic progression attenuates the expression of Nogo-B in autopsied coronary artery: pathology and virtual histology intravascular ultrasound analysis. J Korean Med Sci. 2009;24:596-604 pubmed publisher
Almeida Issa M, Pineiro Maceira J, Farias R, Pureza M, Raggio Luiz R, Manela Azulay M. Immunohistochemical expression of matrix metalloproteinases in photodamaged skin by photodynamic therapy. Br J Dermatol. 2009;161:647-53 pubmed publisher
Jia J, Wang C, Shi Z, Zhao J, Jia Y, Zhao Hui Z, et al. Inhibitory effect of CD147/HAb18 monoclonal antibody on cartilage erosion and synovitis in the SCID mouse model for rheumatoid arthritis. Rheumatology (Oxford). 2009;48:721-6 pubmed publisher
Lin C, Chao T, Yu C, Yu M, Jin J. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 2009;117:162-75 pubmed publisher
del Casar J, Gonzalez L, Alvarez E, Junquera S, Marin L, Gonzalez L, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat. 2009;116:39-52 pubmed publisher
Ullmann U, Gilles C, De Rycke M, Van de Velde H, Sermon K, Liebaers I. GSK-3-specific inhibitor-supplemented hESC medium prevents the epithelial-mesenchymal transition process and the up-regulation of matrix metalloproteinases in hESCs cultured in feeder-free conditions. Mol Hum Reprod. 2008;14:169-79 pubmed publisher
Korpi J, Kervinen V, Mäklin H, Väänänen A, Lahtinen M, Laara E, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer. 2008;98:766-75 pubmed publisher
Boyd S, Tolvanen K, Virolainen S, Kuivanen T, Kyllönen L, Saarialho Kere U. Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls. Virchows Arch. 2008;452:83-90 pubmed
Zhang Y, Du J, Tian X, Zhong Y, Fang W. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. Chin Med J (Engl). 2007;120:1597-605 pubmed
Gonzalez L, Pidal I, Junquera S, Corte M, Vazquez J, Rodriguez J, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007;97:957-63 pubmed
Cho Y, Lee W, Song S, Shin H, Yun S, Chun H. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol. 2007;38:1603-10 pubmed
Kubben F, Sier C, Hawinkels L, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43:1869-76 pubmed
Vizoso F, Gonzalez L, Corte M, Rodriguez J, Vazquez J, Lamelas M, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96:903-11 pubmed
Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M, et al. Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett. 2007;253:34-42 pubmed
Seo Y, Park J, Kim J, Kim J, Yeon J, Kim J, et al. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig Dis Sci. 2007;52:753-9 pubmed
Rönkkö S, Rekonen P, Kaarniranta K, Puustjarvi T, Teräsvirta M, Uusitalo H. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol. 2007;245:697-704 pubmed
El Kenawy A, Lotfy M, El Kott A, El Shahat M. Significance of matrix metalloproteinase 9 and CD34 expressions in esophageal carcinoma: correlation with DNA content. J Clin Gastroenterol. 2005;39:791-4 pubmed
Park K, Hwang S, Sheen S, Oh Y, Han J, Lee K. Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer. Respiration. 2005;72:166-75 pubmed
Sun C, Cheng C, Chien C, Pang J, Ku W, Chen P, et al. Role of matrix metalloproteinase-9 in ex vivo expansion of human limbal epithelial cells cultured on human amniotic membrane. Invest Ophthalmol Vis Sci. 2005;46:808-15 pubmed
Ciborowski P, Enose Y, Mack A, Fladseth M, Gendelman H. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. J Neuroimmunol. 2004;157:11-6 pubmed
Stefanidakis M, Ruohtula T, Borregaard N, Gahmberg C, Koivunen E. Intracellular and cell surface localization of a complex between alphaMbeta2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. J Immunol. 2004;172:7060-8 pubmed
Alami J, Williams B, Yeger H. Derivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer. 2003;107:365-74 pubmed
Zhang S, Li L, Lin J, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003;9:899-904 pubmed
Ratzinger G, Stoitzner P, Ebner S, Lutz M, Layton G, Rainer C, et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol. 2002;168:4361-71 pubmed
Maguen E, Zorapapel N, Zieske J, Ninomiya Y, Sado Y, Kenney M, et al. Extracellular matrix and matrix metalloproteinase changes in human corneas after complicated laser-assisted in situ keratomileusis (LASIK). Cornea. 2002;21:95-100 pubmed

product information

Product Type :

Antibody

Product Name :

MMP9 Monoclonal Antibody (GE-213)

Catalog # :

MA5-13595

Quantity :

500 uL

Price :

US 480.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human

Applications :

Immunohistochemistry (Frozen): Assay-dependent, Immunoprecipitation: 2 ug/mL, Inhibition Assays: 2-4 ug/mL

Species :

Human

Clone :

GE-213

Isotype :

IgG1

Storage :

4 C

Description :

MMP9 (matrix metallopeptidase 9, GELB, CLG4B) is a matrix metalloproteinase, a family of zinc and calcium-dependent endopeptidases that degrade extracellular matrix proteins. MMP9 is secreted as a 92kDa zymogen and cleavage of pro-MMP9 results in the active enzyme with a molecular weight of 82kDa. MMP9 has a gelatin-binding domain consisting of three fibronectin type II units, a catalytic domain containing the zinc-binding site, a proline-rich type V collagen-homologous domain and a hemopexin-like domain. MMP9 is produced by monocytes, macrophages, neutrophils, keratinocytes, fibroblasts, osteoclasts and endothelial cells, and is involved in inflammatory responses, tissue remodeling, wound healing, tumor growth and metastasis. MMP9 is supplied by bone marrow-derived cells and contributes to skin carcinogenesis. Further, MMP9 degrades type IV and V collagens. Studies in rhesus monkeys suggest that the enzyme is involved in IL-8-induced mobilization of hematopoietic progenitor cells from bone marrow, and murine studies suggest a role in tumor-associated tissue remodeling. Studies have shown that elevated MMP9 is associated with progression of idiopathic atrial fibrillation and aortic aneurysm.

Immunogen :

Purified human MMP-9

Format :

Liquid

Applications w/Dilutions :

Immunohistochemistry (Frozen): Assay-dependent, Immunoprecipitation: 2 ug/mL, Inhibition Assays: 2-4 ug/mL

Aliases :

67 kDa matrix metalloproteinase-9; 82 kDa matrix metalloproteinase-9; 92 kDa gelatinase; 92 kDa type IV collagenase; 92kD gelatinase; 92kD type IV collagenase; 92kDa gelatinase; 92kDa type IV collagenase; 92-kDa type IV collagenase; AW743869; B/MMP9; Clg4b; collagenase type IVB; fj05a08; Gel B; gelatinase B; Gelatinase-B; GELB; macrophage gelatinase; MANDP2; matrix metallo protease; matrix metallopeptidase 9; matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); matrix metalloproteinase 9; matrix metalloproteinase 9 (gelatinase B 92-kDa type IV collagenase); matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); matrix metalloproteinase 9 (gelatinase B, 92kDa matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); matrix metalloproteinase 9 (gelatinase B, 92-kDa type IV collagenase); Matrix metalloproteinase9; matrix metalloproteinase-9; MMP; Mmp9; MMP-9; mmp9 protein; MMP-9 protein; MMPs; Preproform of 92-kDa type IV collagenase (MMP-9): N-terminal; pro-MMP-9; type IV collagenase; type V collagenase; wu:fb02g06; wu:fb07b05; wu:fi98c09; wu:fj05a08; ZFMMP-9; zgc:64165